MedTrace Logo

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)

NCT06025344 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-11-21

No results posted yet for this study

Summary

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, single dose oral relative bioavailability study of a novel PanCytoVir™ oral suspension (100 mg/mL) versus probenecid 500 mg tablets in normal healthy, adult, human subjects under fasting conditions.

Conditions

  • Relative Bioavailability

Interventions

DRUG

PanCytoVir™ 100 mg/mL oral suspension

Single oral dose of 1000 mg (100 mg/mL) under fasted conditions

DRUG

Probenecid 500 mg

Single oral dose of 1000 mg under fasted conditions

Sponsors & Collaborators

  • TrippBio, Inc.

    lead INDUSTRY

Principal Investigators

  • David E Martin, PharmD · TrippBio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2024-09-30
Completion
2024-10-15

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06025344 on ClinicalTrials.gov